Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology | Nephrology/Urology
Bladder Cancer
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Bladder Cancer Database
Phase II Randomized Trial of Gemcitabine and Cisplatin with or without Cetuximab in Patients with Urothelial Carcinoma
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
SWOG S0306: A Phase II Study of Irinotecan in Patients
with Advanced Transitional Cell Carcinoma of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
A multicenter trial of adjuvant chemotherapy in organ-confined Bladder Cancer based on p53 status
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Bladder Cancer
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer - Adults
Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer - Adults
Bladder Cancer- Adults
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Randomized, Comparative, Controlled Phase III, Multicenter Study of Hexvix Fluorescence Cystoscopy and White Light Cystoscopy in the Detection of Papillary Bladder Cancer and Early Recurrence rate in Patients with Bladder Cancer.
This study involves the injection of certain peptides and an immune system stimulating substance to try to stimulate the immune system to recognize and kill tumor cells.
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Carcinoma Of The Bladder
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Bladder Tissue Bank
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium